Clinical Trials Logo

Microangiopathy clinical trials

View clinical trials related to Microangiopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03246542 Completed - HELLP Syndrome Clinical Trials

Promising Bimarker Prediction of Outcome of HELLP Syndrome.

Start date: January 1, 2015
Phase: N/A
Study type: Observational [Patient Registry]

HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia. And may occasionally be confused with other diseases complicating pregnancy such as acute fatty liver of pregnancy, gastroenteritis, hepatitis, appendicitis, gallbladder disease, immune thrombocytopenia, lupus flare, antiphospholipid syndrome, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and nonalcoholic fatty liver disease. The distinction between thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and severe preeclampsia is important for therapeutic and prognostic reasons. However, the clinical and histological features are so similar that establishing the correct diagnosis is often difficult; furthermore, these disorders may occur concurrently.

NCT ID: NCT03232359 Completed - HELLP Syndrome Clinical Trials

Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome

Start date: January 1, 2015
Phase: N/A
Study type: Observational [Patient Registry]

Immature platelet fraction is a non-invasive test of real time thrombopoiesis. High IPF% has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption. IPF% is able to discriminate between patients with TTP/HUS or SPE/HELLP